

Update on FDA's Guidance for Industry #213



Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria

June 22, 2016

William T. Flynn
FDA Center for Veterinary Medicine

FDA's Judicious Use Strategy

Key Documents:



FDA's Judicious Use Strategy

In 2012, FDA published **Guidance for Industry (GFI) #209** describing the overall policy direction regarding antimicrobial drugs.

Key principles are :

Limit use of medically important antimicrobial drugs in food-producing animals to those uses

1. considered necessary for ensuring animal health.
(therapeutic uses)
2. that include veterinary oversight or consultation.

FDA's Judicious Use Strategy

In 2013, **GFI #213** was published, providing more detail on implementing the key principles in Guidance #209

- Defines “medically important”
 - (i.e., define what products are affected)
- Established 3-year timeline to:
 - Voluntarily remove claims relating to production uses
 - Bring the remaining therapeutic uses under veterinary oversight by changing marketing status from over-the-counter (OTC) to veterinary feed directive (VFD) or prescription (Rx)

FDA's Judicious Use Strategy

Veterinary Feed Directive (VFD) Regulation

- Requirements relating to distribution and use of VFD drugs (feed-use drugs that require supervision of licensed veterinarian)
- Existing VFD regulations amended to improve efficiency of the process
- Updated regulations went into effect October 2015
- Critical step for facilitating transition to veterinary oversight

Products affected by GFI #213

- “Medically important” antibiotics administered in feed or drinking water including:
 - Aminoglycosides
 - Lincosamides
 - Macrolides
 - Penicillins
 - Streptogramins
 - Sulfonamides
 - Tetracyclines

Timeline Summary

- Guidance #213 established a 3-year timeline to implement changes to affected products
- Target date for aligning all affected products with the key principles is January 1, 2017
- Once changes are made to affected products, it will be illegal to use products for growth promotion or to use without the authorization of a licensed veterinarian

Status Update

- 293 approved drug applications were identified as being affected by GFI #213
- Includes pioneer, generic, and combination approvals
- All affected drug sponsors have committed in writing to voluntarily align their products
- Detailed discussions held with pharmaceutical industry to outline a process for coordinating changes to products
- Detailed administrative process was communicated to all affected sponsors in a September 2015 letter

Status Update

- Some changes have already been made, including:
 - 4 applications have been converted from OTC to Rx
 - Production use withdrawn from 1 application
 - 41 applications have been completely withdrawn
- However, by design, the changes are expected to occur in a coordinated fashion at the end of this year – such that all changes are in effect January 1, 2017.

Communication and Outreach

- Since June 2015, CVM employees have:
 - Given at least 60 presentations on “Medically Important Antimicrobials in Animal Agriculture.”
 - This presentation is also posted online and has been accessed 2,413 times in the last 8 months.
 - Published and distributed stakeholder specific Veterinary Feed Directive brochures
 - Published two guidance documents to support implementation of VFD regulation
 - Updated the medicated feed label website

Future Communication and Outreach

FDA is currently:

- Engaging USDA on the creation of a new education module specifically aimed at the VFD Rule for accredited veterinarians
- In the process of creating stakeholder specific educational videos that will be made available online

For a reference list of AMR and VFD related material, please see the following

<http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/ucm464991.htm>

What happens after January 2017?

- Guidance #213 will implement some very important changes to how antibiotics have been used for decades, but more work is needed
- FDA is currently developing an action plan outlining additional steps needed to build on the progress made under the GFI #213 initiative
- The goal is to publish this action plan before the end of this calendar year.

Thank You

